GILLES DIVITA
CEO Divincell
Dr. Gilles DIVITA is founder and CEO of DIVINCELL and CSO at AANASTRA LLC, California (USA) a BioPharmaceutical NanoMedicine Start-up pioneering a novel RNA therapeutic drug delivery for the treatment of cancer and genetic diseases . Dr. DIVITA has over 25 years of experience in drug delivery systems, peptide-drugs and oligonucleotide therapeutics. Dr Divita is the pioneer of the “non covalent cell penetrating peptide-based strategy” for therapeutic delivery and inventor of the peptide-based platform for RNA therapeutic strategy. Dr. Divita holds a Ph.D. in Biochemistry/Biophysic from the University in Lyon, France. He worked as a Scientist at the Max Planck Institute for Medical Research in Heidelberg-Germany and then as Associate Professor at the SCRIPPS Research Institute, La Jolla, USA. In 1996, Dr. Divita joined the French National Center for Scientific Research (CNRS) and was Research Director, Head of Chemical Biology and Nanotechnology for the Therapeutics Team at the CNRS in Montpellier-France from 1999 to 2016.
Seminars
- Rationally designing and optimizing AI-driven peptide-vectors for targeted delivery of different payloads including peptide, protein and RNA
- Demonstrating safety and characterization of peptide-based nanoparticles for extrahepatic delivery of RNA
- Leveraging a peptide-based nanoparticle platform for systemic targeted delivery of therapeutic mRNA: T cell engineering and tumor selectivity
NEW COMPANY
